BioVaxys Technology Secures Funding Through Convertible Debenture

Author: Evelyn Baker Updated: 09-16-2025 05:57 AM

BioVaxys Technology Corp. Closes Convertible Debenture Offering

BioVaxys Technology Corp. (CSE: BIOV) has recently achieved a significant milestone by successfully closing a private placement of unsecured convertible debentures. This offering, which garnered attention for its potential impact, raised a total of approximately $335,670.

Details of the Convertible Debentures

The convertible debentures are noteworthy for their unsecured status and have a maturity date set for August 30, 2026. They yield an interest rate of 10% per annum, with interest payments made quarterly. As a unique feature, holders of these debentures have the option to convert the principal amount into common shares of BioVaxys at the market price on the day of conversion notice.

Warrants Issued with Debentures

Investors participating in the offering were rewarded with 4,000 transferable common share purchase warrants for every $1,000 invested in debentures. These warrants allow holders to purchase common shares at an exercise price of $0.25 until September 15, 2026.

Utilization of Proceeds from the Offering

The funds raised through this offering will be allocated toward various strategic initiatives, including research and development, working capital, and general corporate expenses. BioVaxys is committed to using these funds to propel its innovative projects further.

Insider Participation in the Offering

Interestingly, notable insiders of BioVaxys participated in this offering, contributing a total of $50,000. James Passin, the Chief Financial Officer, and Kenneth Kovan, the Chief Operating Officer, each purchased $25,000 worth of debentures. This participation underscores the confidence that insiders have in BioVaxys' future prospects.

About BioVaxys Technology Corp.

BioVaxys Technology Corp. is a forward-thinking biopharmaceutical company focusing on immunotherapy innovations. Its proprietary technologies, including the DPX™ immune-educating platform and the HapTenix© tumor construct platform, aim to improve therapeutic outcomes for conditions like cancer and various immunological diseases. Their clinical pipeline includes promising candidates like maveropepimut-S (MVP-S), currently undergoing Phase IIB studies for complex cancers.

For more information on BioVaxys, you can visit their official website.

Frequently Asked Questions

What is the significance of the recent offering by BioVaxys?

The recent offering allows BioVaxys to secure funding for its innovative research and development initiatives while enhancing its financial stability.

What are the terms of the convertible debentures?

The convertible debentures yield a 10% interest rate and can be converted into shares at market price, with a maturity date set for August 30, 2026.

Who are the insiders participating in the offering?

Notable insiders, including Chief Financial Officer James Passin and Chief Operating Officer Kenneth Kovan, participated by investing a total of $50,000 in the debentures.

What is BioVaxys's focus as a company?

BioVaxys focuses on developing immunotherapies for cancer and other immunological diseases, utilizing cutting-edge technologies for enhanced treatment outcomes.

How will the proceeds from the offering be used?

The proceeds will go toward research and development, working capital, and general corporate expenses, aiming to further advance BioVaxys's innovative projects.

About The Author

Greetings, I'm 32-year-old author and financial specialist Evelyn Baker. My introduction into the financial industry started with an economics degree and continued with a wealth of experience in wealth management and financial consulting. My great passion over the years has been assisting people and companies in making wise, well-informed decisions to reach their financial objectives.

My goal with writing is to simplify difficult financial ideas into understandable, doable guidance. My goal in writing many books and articles is to make personal finance understandable to everyone, irrespective of their experience or background. I want to give readers the information they need to take charge of their financial futures, from investing and retirement planning to budgeting and saving.

Along with my writing, I lead webinars and workshops where I provide doable advice and methods for achieving financial success. To reach a larger audience, I also frequently contribute to financial blogs and publications. My method is always to offer doable, real-world guidance that can actually improve people's lives.

Aside from my job, I like to cook, travel, and experience other cultures. I work hard to apply my belief in the value of a balanced life to my financial counsel. My goal in working is to encourage and enable people to succeed financially so they may lead the best lives possible.

Contact Evelyn Baker privately here. Or send an email with ATTN: Evelyn Baker as the subject to contact@investorshangout.com.

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.